Latest stories on NTHI
NeOnc Reports Third-Quarter Results and Clinical Progress
TipRanks58 · neutralearnings
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
GlobeNewswire63 · neutralgeneral
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
StockTitan64 · neutralgeneral
NeOnc Technologies Expands Abu Dhabi Oncology Collaboration Efforts
TipRanks58 · neutralproduct/pr
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
Business Insider58 · neutralproduct/pr
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
Business Insider63 · neutralproduct/pr
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
GlobeNewswire63 · neutralproduct/pr
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
Business Insider56 · neutralproduct/pr
NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
GlobeNewswire67 · bullishgeneral
NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
StockTitan67 · bullishgeneral
NeOnc Plans FDA End-of-Phase 1 Meeting for NEO212
TipRanks59 · neutralproduct/pr
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
4 Explosive Stories Enter the Investor Spotlight
GlobeNewswire57 · neutralgeneral
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
Business Insider63 · neutralproduct/pr
Here’s What Investors Are Watching, Including $20 Price Target Bombshell
GlobeNewswire65 · bullishanalyst
Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals
GlobeNewswire57 · neutralgeneral
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) files 8-K
SEC 8-K50 · neutralgeneral
NTHI Highlights Phase 2a Signal for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
September 21, 2026
MarketChameleon67 · bullishproduct/pr
NeOnc Charting New Nasal Route to Treating Brain Cancer
Business Insider78 · bullishproduct/pr
NTHI Redeems All Series A Preferred Shares, Removing a Discounted Conversion Overhang
September 18, 2026
MarketChameleon73 · bullishgeneral
NeOnc Technologies redeems all $6M Series A preferred stock
Seeking Alpha28 · bearishgeneral